After liver transplantation, a relatively low intensity immunosuppressive regimen is employed in our unit: after initial triple therapy (prednisolone, azathioprine, cyclosporin), prednisolone is discontinued at three months and azathioprine at one year. A retrospective study was therefore performed to determine the incidence of rejection, and to identify risk factors for rejection in our patient population.
ous factors, including improved timing of transplantation, increased experience in medical management, better immunosuppressive regimens, and advances in liver transplant surgery. The use of reduced-size grafts has expanded the population of young patients for whom suitable donors are available, and liver transplantation in the first year of life is now commonplace."5 Despite these advances, there is still considerable post-transplant morbidity, and retransplantation is often necessary.' 2 Rejection is common and remains an important cause of allograft failure.2 6 Immunosuppression is associated with a high incidence of complications, infection being the most frequent cause of death after transplantation.78 We have employed an immunosuppressive regimen which is less intense than those utilised in other centres.' 26 9 12 The aims of this study were therefore to determine the impact of rejection on our patient population, and to identify potential risk factors for rejection.
Patients and methods

PATIENTS
A retrospective study was carried out in June 1993 on the 109 children who had undergone liver transplantation between 1983 and 1993 in the paediatric liver transplant programme in Birmingham. The case records were reviewed, and the histological results were reassessed in cases in which rejection had been reported, in order to systematically grade severity.
Of the 109 children transplanted, 24 required a second transplant, and two a third, so that in total 135 transplants were performed. The recipients ranged in age from 8 weeks to 15 years (median 2.5 years). Reduced size grafts were employed in 74 (55%) of the procedures, and 34 (25%) of the transplants were in subjects less than 1 year old. There were 51 male and 58 female recipients. All donor/recipient matches were ABO blood group compatible. The median period of posttransplant follow up was 55 weeks (range 0-8.1 years).
The primary disorders leading to transplantation were extrahepatic biliary atresia (51), fulminant hepatic failure (19) , cryptogenic cirrhosis (11), a1-antitrypsin deficiency (10), tyrosinaemia type 1 (five), Wilson's disease (three), primary oxalosis (two), hepatoblastoma (two), infantile haemangioendothelioma (one), cystic fibrosis (one), Caroli's disease (one), primary sclerosing cholangitis (one), Crigler-Najjar syndrome (one), and propionic acidaemia (one). Indications for retransplantation were graft ischaemia due to vascular occlusion (12) , chronic rejection (eight), primary non-function of the graft (four), and graft failure associated with suspected viral hepatitis (two).
POST-TRANSPLANTATION IMMUNOSUPPRESSION PROTOCOL
After transplantation, initial immunosuppression consisted of triple therapy with corticosteroids, azathioprine, and cyclosporin. Hydrocortisone (< 10 kg body weight, 100 mg; > 10 kg body weight, 200 mg; divided twice daily, administered intravenously) and azathioprine (2 mg/kg, once daily, administered intravenously) were started immediately. Cyclosporin (2 mg/kg, administered intravenously twice daily) was begun within 24 hours, provided that the urine output was satisfactory. When medication was switched to oral, hydrocortisone was replaced with prednisolone (2 mg/kg daily). The dose of prednisolone was gradually reduced after two or three weeks, and, except in those patients with active rejection, it was discontinued three months after transplantation. The dose of cyclosporin was adjusted to achieve whole blood trough concentrations in the range 100-300 ng/ml. Concentrations at the upper end of the range were maintained during the early months after transplantation, but those less than 150 ng/ml were considered adequate after the first year. Azathioprine was discontinued one year after transplantation.
REJECTION: DIAGNOSIS AND TREATMENT
In the post-transplant period, liver biopsy was performed when indicated on the basis of clinical manifestations and abnormal liver function tests. In practice, most children underwent at least one biopsy in the early weeks. Protocol annual biopsies were also performed.
The diagnosis of acute rejection was based on three main histological features: (1) a mixed portal inflammatory infiltrate; (2) inflammatory damage to bile ducts; (3) venous endothelial inflammation.'3 14 Each of these three features was graded semiquantitatively on a scale of 0 to 3 (O=absent; 1 =mild; 2=moderate; 3=severe). The individual scores were added together to produce a final rejection score of 0-9. This score was converted to a rejection grade as follows: 0-2=absent; 3=borderline; 4-5=mild; 6-7=moderate; 8-9 = 
The diagnosis of chronic rejection was based on the demonstration of interlobular bile duct loss from at least 50% of portal tracts. For the purposes of this study we examined the incidence of irreversible chronic rejectionthat is, chronic rejection that eventually led to graft failure-in order to avoid difficulties of histological interpretation in borderline cases of chronic rejection.
Based on the degree of clinical and biochemical disturbances present and on the severity of the histological changes, acute rejection was treated with intensified immunosuppression. Treatment consisted of a three day course of methylprednisolone (20-40 mg/kg once daily, intravenous). One patient with refractory rejection was treated with OKT3. Seven patients who showed signs of steroid resistant rejection were given FK506 instead of cyclosporin.
VIRAL SURVEILLANCE Donor and recipient cytomegalovirus (CMV) status and recipient Epstein-Barr virus (EBV) status were determined serologically before transplantation, and at regular intervals thereafter. Diagnosis of infection was based on the demonstration of significant changes in serological titres. In some cases further evidence of infection was available based on viral culture or immunohistochemistry.
STATISTICAL ANALYSIS
The following parameters were evaluated as possible risk factors for the development of rejection: the age and sex of recipient and donor, the type of graft employed (whole v reduced size), the occurrence of CMV or EBV infection, the recipient's nutritional status (height for age, weight for age, skinfold thickness), the primary indication for transplantation, and transplantation date. In order to minimise possible confounding effects of early graft loss from other causes, the incidences of acute rejection and irreversible chronic rejection were analysed in those grafts that survived for more than one week or four weeks respectively. Donor and recipient age and sex, graft type, and transplantation date were investigated as potential risk factors for acute rejection by logistic regression for the probability of rejection, and Cox regression for the survival time in days from transplantation to the onset of rejection as implemented in the EGRET statistical package (Statistics and Epidemiology Research Corporation, Seattle, WA, USA).
Results
Of the 135 allografts employed in these patients, 34 were lost during the first week and 44 during the first four weeks after transplantation. These grafts failed because of primary non-function, ischaemic injury, or patient death.
Acute rejection occurred in 51 (50%) of the 101 allografts which survived beyond the first week, and a total of 60 separate episodes of acute rejection were documented. The changes were graded as mild in 20, moderate in 25, and severe in six cases. The median interval from transplantation to the diagnosis of acute rejection was nine (range 3-44) days. In 48 of the 51 affected grafts (94%) the process was first identified within 21 days of transplantation, at which time all were still receiving high dose prednisolone (1.5-2 mg/kg per day). In 42 cases there was just one episode of acute rejection, but in nine there was a second episode, occurring between two and 54 (median nine) weeks after the first. Acute rejection occurred in four cases after discontinuation of corticosteroids at three months, but in two of these the doses of azathioprine and cyclosporin had also been reduced because of suspected infection.
In total, 40 On investigation by logistic regression for the probability of rejection and Cox regression for the survival time in days from transplantation to the onset of rejection, patient age at transplantation emerged as a significant risk factor for acute rejection. Figure 2 shows survival curves representing the time interval to the development of acute rejection for three separate recipient age groups (0-1 year, 1-3 years, over 3 years) during the first 45 days after transplantation. The numbers of subjects in these groups were 28, 28, and 45 respectively, and the percentages developing acute rejection were 29, 57, and 60. The median numbers of days to rejection in these subject groups were 12 (95% confidence interval (CI) 7 to 35), 10 (95% CI 7 to 14), and 8 (95% CI 7 to 9). The reduced risk for acute rejection in the younger patients is confirmed by the statistical significance of the difference in survival curves (p<0.03).
There was no significant correlation between indicators of nutritional status, including weight, height, and subscapular and triceps skinfold measurements, before transplantation and the subsequent incidence of acute rejection or irreversible chronic rejection. Height Z scores at transplantation were lower in those who did not develop acute rejection (-1.6 v -0.5), but this difference was not significant.
There was no apparent association between either CMV or EBV infection and the development of acute rejection or irreversible chronic rejection. Neither were any of the various primary liver disorders associated with an increased risk of rejection after transplantation.
Discussion
Rejection is an important cause of morbidity and mortality after liver transplantation. Acute rejection is treated with intensified immunosuppression, but unfortunately this may cause significant complications. Chronic rejection often leads to allograft failure and in these cases retransplantation is necessary if the patient is to 1.00 later developed chronic rejection. total of 60 documented episodes of acute ure 2 Survival curves representing time to the development of acute rejection during rejection in our patients occurred after disconfirst 45 days after transplantation. Patients are grouped by age at transplantation: 0-1 tinuation of prednisolone, and in two of these r (n=28); 1-3 years (n=28); >3 years (n=45). The role of age as a risk factorfor acute cases the patients were on reduced doses of ction is supported by the statistical significance of the difference between the survival azathioprine and cyclosporin because of susves (p<O.03).
pected infections. Importantly, in nine of the survive. Corticosteroids increase the risk of 11 cases of irreversible chronic rejection in our serious bacterial infections and of opportunis-series, persistent acute rejection had already tic infection with CMV, Pneumocystis carinii, begun in the early weeks after transplantation, and aspergillus.'l '-`Long term corticosteroid and so prednisolone had not been discontinued treatment may lead to the development of in these patients. The practice of withdrawing cataracts, aseptic hip necrosis, bone deminer-steroids at three months did not therefore alisation, and growth retardation. Azathioprine appear to contribute significantly to the may increase susceptibility to opportunistic incidence of acute rejection or irreversible infections, and may be associated with an chronic rejection in our patients. The most surprising observation in this employed.23 Although histological definitions study was that transplantation during the first of chronic rejection exist, recovery is possible in year of life was associated with a significantly some of these cases, and so for the purposes of reduced risk of rejection. Among those transthis study we looked at those cases in which the planted before 1 year of age, the incidence of process proved to be irreversible, resulting in acute rejection was approximately half of that eventual graft failure. Previous experience has in older recipients, and graft failure from shown that acute rejection may evolve into chronic rejection did not occur. The published chronic rejection.6 20 This pattern was observed literature has not previously suggested that in our patients, in that acute rejection had been allograft rejection is less common after liver, dnocumeintedA in e-achl of the-n1 allorafts in 10 28 Our finding was therefore an unexpected one. If age at transplantation is truly a significant risk factor for rejection, this would be of great biological interest and an important clinical observation. However, given that this is a retrospective study covering a period of 10 years, caution is necessary in interpreting the results. With the introduction of reduced size liver grafts, infant transplantation gradually became more frequent during the period covered by this study. If, in parallel with this change in transplantation age, there were to have been unrecognised but significant changes in clinical practice or subtle changes in the histological criteria employed in the diagnosis of rejection, this might have led to a non-causal association between age at transplantation and rejection risk. For this reason, the statistical analysis performed in this study was designed to take account of any unrecognised effects that might be linked to transplantation date. Age at transplantation emerged as an independent risk factor for rejection. Nevertheless, in order to confirm or refute the validity of this observation, it is essential that studies should now be performed on other large paediatric transplant populations, in which all post-transplant biopsies are assessed at the end of the study by an individual histopathologist, blinded to patient age.
If age is confirmed as a risk factor for rejection, the biological basis for this phenomenon would be of great interest. A recent study of adult patients in the Birmingham programme demonstrated a significantly lower incidence of chronic rejection in recipients over 30 years of age.23 It is possible that this might have been due to an age related alteration in immune function, with reduced alloreactive responsiveness in older patients.3' The phenomenon whereby allograft tolerance is readily induced in laboratory animals in early life may be relevant to our findings.32
